MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives

T Ram, AK Singh, A Kumar, H Singh, P Pathak… - RSC Medicinal …, 2023 - pubs.rsc.org
MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway
that regulates a variety of cellular functions including proliferation, survival, and …

Hepatocellular carcinoma: past and present challenges and progress in molecular classification and precision oncology

P Coffin, A He - International Journal of Molecular Sciences, 2023 - mdpi.com
Hepatocellular carcinoma (HCC) is one of the most common solid tumor malignancies in the
world and represents roughly 90% of all primary malignancies of the liver. The most …

Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic …

S Zhang, HF Yao, H Li, T Su, SH Jiang, H Wang… - Cellular Oncology, 2023 - Springer
Abstract Purpose Transglutaminases (TGs) are multifunctional enzymes exhibiting
transglutaminase crosslinking, as well as atypical GTPase/ATPase and kinase activities …

Identification of a novel circRNA–miRNA–mRNA regulatory axis in hepatocellular carcinoma based on bioinformatics analysis

G Zhong, Y Lin, Z Huang - Scientific Reports, 2023 - nature.com
In recent years, circular RNAs (circRNAs) have been found to play an essential regulatory
role in hepatocellular carcinoma (HCC) through various mechanisms, particularly the …

Enhancement of Anticancer Effects by Combining 5-Fluorouracil with Refametinib in Human Oral Squamous Cell Carcinoma Cell Line

PC Chen, BC Su, TL Ma, YC Hong, YW Chen, TTT Vo… - Applied Sciences, 2023 - mdpi.com
(1) Background: Oral squamous cell carcinoma (OSCC) is a significant health burden
worldwide. This study aimed to determine the potentials of Refametinib, an orally …

[PDF][PDF] Analisi molecolare di carcinomi epatocellulari istologicamente caratterizzati e correlazioni eziopatogenetiche

E Unti - 2023 - tesidottorato.depositolegale.it
1. OBIETTIVI Il carcinoma epatocellulare (HCC) si caratterizza per una predominante
resistenza alla chemioterapia sistemica e, per tale ragione, per diversi anni non ha avuto …